Novo Nordisk Navigates Obesity Drug Market Turbulence

Novo Nordisk has reported better-than-expected first-quarter profits, driven by demand for its new weight-loss drug, Wegovy. However, competition with Eli Lilly is intensifying, following Lilly's approval for a rival drug. Novo Nordisk faces challenges including trial setbacks, sales declines, and a significant share price drop over the past year.

Novo Nordisk, the renowned maker of the weight-loss drug Wegovy, has announced first-quarter profits that exceed analysts' forecasts. The Danish company reported an adjusted operating profit of 32.86 billion Danish crowns ($5.16 billion), outstripping the expected 28.74 billion. This accomplishment comes amid growing competition from U.S. rival Eli Lilly.

The pharmaceutical giant is pinning its hopes on the success of its new weight-loss pill amidst the competitive strain with Eli Lilly, which has intensified since the FDA approved Lilly's competing drug Foundayo. Novo's share price, which had plummeted by almost 40% over the past year, has begun to stabilize on optimistic forecasts for the Wegovy pill.

Under CEO Mike Doustdar's leadership, Novo Nordisk is striving for recovery as it contends with previous challenges, including disappointing trial outcomes, declining sales, and a massive erosion of market value since its 2024 peak. Meanwhile, Eli Lilly's profit forecasts have improved, thanks to strong demand for its own weight-loss and diabetes treatments.